Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung

R.J. Roeleveld, A. Vonk Noordegraaf, W. van der Bij, P.E. Postmus, A. Boonstra
European Respiratory Journal 2003 21: 192-194; DOI: 10.1183/09031936.03.00020902
R.J. Roeleveld
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Vonk Noordegraaf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. van der Bij
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.E. Postmus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Boonstra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Before prostacyclins became available, lung or heart/lung transplantation was the only effective treatment for patients with primary pulmonary hypertension (PPH) who deteriorated under supportive medical treatment. Unfortunately, acute and chronic rejections occur in a large number of cases, limiting the average survival to 4.5 yrs.

A female patient, age 35 yrs, was diagnosed with PPH and underwent single lung transplantation. Despite aggressive immunosuppressive therapy, the patient had several episodes of acute rejection. Eventually, chronic rejection with bronchiolitis obliterans developed. After 5 yrs, the donor lung was no longer functional. The patient was in New York Heart Association (NYHA) class 4, had a 6‐min walking distance of 50 m and a resting arterial oxygen tension (Pa,O2) of 9.8 kPa (74 mmHg) when using 3 L·min−1 of oxygen.

Epoprostenol treatment was started and the patient showed remarkable improvement. After 17 months the patient was NYHA class 2, walked 503 m in 6 min and had a resting Pa,O2 of 10.9 kPa (82 mmHg) without supplemental oxygen.

In this patient, treatment with epoprostenol was effective after rejection of a single donor lung transplanted for primary pulmonary hypertension.

  • epoprostenol
  • pulmonary hypertension
  • single lung transplantation

Primary pulmonary hypertension (PPH) is a rare, progressive disease with poor prognosis. Until only a few years ago, treatment consisted of supportive care, calcium antagonists and lung transplantation (LTx). However, transplant dysfunction because of rejection remains a major complication. For transplantations performed between 1991 and 1995 in the Netherlands for pulmonary hypertension, 2‐yr survival is limited to ∼50% 1, 2.

Over the last few years, treatment of PPH with prostacyclins has proven effective 3. Initially considered as a bridge to transplantation, it is now thought that prostacyclins enable postponing of transplantation for a longer period of time, possibly even indefinitely 4. This case report describes the course of a patient who underwent single LTx for PPH at the time when prostacyclins were not available for long-term treatment.

Case report

A 35-yr-old female was diagnosed with pulmonary hypertension in late 1993. Secondary pulmonary hypertension was ruled out using laboratory and pulmonary function tests, high-resolution computed tomography, ventilation-perfusion scintigraphy and echocardiography. Although the patient had taken an undocumented dose of dexfenfluramine as a teenager, the final diagnosis was PPH. In 1995, further investigation was carried out, including acute vasodilator testing. During this test, the pulmonary artery pressure (PAP) decreased from 95/35/68 mmHg to 80/28/48 mmHg (−29%) after increasing doses of epoprostenol. There was no beneficial response on high levels of oxygen. Because of the diagnosis of PPH and subsequent deterioration of the patient's condition under supportive treatment with oxygen, oral anticoagulants and digoxin, the patient was listed for LTx.

At that time, only single LTx was performed for PPH in the Netherlands. Within a year after listing, an uncomplicated transplantation of the right lung was performed. Postoperative PAP was 36/11/19 mmHg. Ventilation-perfusion scintigraphy revealed an equal distribution of ventilation over both lungs, but 89% of the blood flow passed through the transplanted lung.

Immunosuppressive therapy consisted of antithymocyte globulins for induction, and corticosteroids, cyclosporin and azathioprine as maintenance therapy. Nevertheless, very frequent episodes of acute rejection occurred. Within 8 months after transplantation, the first signs of bronchiolitis obliterans were found in an open-lung biopsy. More aggressive immunosuppression with corticosteroids, tacrolimus and mycophenolate mofetil resulted in reduction of the frequency of acute rejections, but failed to halt the progression of bronchiolitis obliterans. Four and a half years after transplantation all functionality of the transplanted lung had been lost. Neither ventilation nor perfusion were detectable over the lung. Chest imaging showed remains of the donor lung and rightward shift of the heart (fig. 1⇓).

Fig. 1.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.—

Chest magnetic resonance imaging (MRI) after donor lung rejection, transverse plane. RV: right ventricle; RA: right atrium; LV: left ventricle; LA: left atrium. The right hemithorax is filled with the remains of the transplanted lung and the heart. Note the severe enlargement of the RA and RV. Although not clearly visible on this image, the atrial septum was intact. The image was acquired with a black-blood prepared 2‐dimensional turbo gradient echo pulse sequence. By using electrocardiogram triggering, the timing of image acquisition was adjusted during mid- to end-diastole of the cardiac cycle 5.

At that time, the patient was severely dyspnoeic at rest, in New York Heart Association (NYHA) functional class 4 and had a 6‐min walking distance of 50 m. Blood gas analysis revealed a resting arterial oxygen tension (Pa,O2) of 9.8 kPa (74 mmHg) when using 3 L·min−1 of oxygen. Retransplantation was considered. However, in the time that had passed since transplantation, epoprostenol had been registered in the Netherlands for use in PPH.

At right heart catheterisation, a PAP of 111/36/61 mmHg was found without any acute response on epoprostenol (table 1⇓). Long-term epoprostenol therapy was started with an initial dose of 4.7 ng·kg−1·min−1 (500 mcg·24 h−1), followed by an average monthly increase of 1 ng·kg−1·min−1. Within a month, the patient was less dyspnoeic and the 6 MWD had increased from 50 to 325 m. After 3 months, supplemental oxygen was discontinued, without negative effect on the exercise capacity. In the following months, the 6 MWD remained stable at ∼350 m, but eventually increased to 503 m (fig. 2⇓). Blood gas analysis showed a Pa,O2 of 10.9 kPa (82 mmHg) without supplemental oxygen after 17 months of epoprostenol therapy. The patient is now classified as NYHA functional class 2 and generally feeling well. No right heart catheterisation was performed during the follow-up period, considering the fact that the findings would not affect the therapy in any way.

Fig. 2.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.—

Six-min walk test results (□) and Borg dyspnoea score (┘).

View this table:
  • View inline
  • View popup
Table 1

Haemodynamic measurements before transplantation (BT), after complete donor lung rejection (LR) and after 17 months of epoprostenol therapy (ET)

Discussion

Findings at the histological examination of the explanted right lung were consistent with the diagnosis of PPH, stage IV–V: intima proliferation, media hypertrophy and plexiform lesions were seen.

According to present standards, this patient should have been considered reversible at the vasodilator test before transplantation, as the decrease in PAP was>20%. The decision to list this patient for LTx immediately, without attempting treatment with calcium-channel blockers first, was not fully justified. Lack of experience with this rare disease and perhaps some confusion due to the difference in response on oxygen and epoprostenol may well have lead to this decision. The rapid deterioration under supportive care alone made listing for LTx a logical choice at that time.

Whether single or bilateral LTx is most beneficial for patients with PPH in general remains uncertain. Although some authors have noted that bilateral LTx has a somewhat better survival 6 and single LTx may result in significant ventilation/perfusion mismatches 7, single LTx is a well accepted modality 8–9. More than 5 yrs after transplantation, chest imaging of the patient showed a fully sclerotic, collapsed donor lung, as a result of ongoing bronchiolitis obliterans and transplant vasculopathy. The patients survival on a prostacyclin-treated native lung enabled the development of a severe stage of bronchiolitis obliterans in the transplant, which is unusual and obviously not compatible with life.

To the best of the authors' knowledge, no literature was available on the use of epoprostenol after LTx and subsequent rejection. The decision to start this therapy rather than listing for retransplantation was therefore based upon the general treatment algorithm for PPH patients 10 as follows: 1) no response during vasodilator testing, 2) NYHA functional class III or IV, and 3) no listing for transplantation unless epoprostenol therapy fails. This case demonstrates that epoprostenol treatment can be effective after single LTx and subsequent rejection. Furthermore, it is demonstrated that patients who are initially not treated with prostacyclins, can still benefit from that form of treatment in a later stage of their disease, even with only one lung with severe PPH.

With hindsight, several therapeutic decisions concerning this patient have been controversial at best. The use of single lung transplantation as an unexpected bridge to epoprostenol treatment did however result in a long survival (>8 yrs after the diagnosis) and a good exercise capacity.

Acknowledgments

Figure 1⇑ was supplied courtesy of J.T. Marcus, Dept of Clinical Physics and Informatics, VU University Medical Center, Amsterdam, the Netherlands.

  • Received March 14, 2002.
  • Accepted June 14, 2002.
  • © ERS Journals Ltd

References

  1. ↵
    de Boer WJ, Mannes GP, Meuzelaar JJ, Brenken UP, van der Bij W, Loef B. Results of 75 lung transplantations performed in Groningen in 1990–1995. Lung Transplantation Group Groningen. Ned Tijdschr Geneeskd 1996;14:1362–1366.
    OpenUrl
  2. ↵
    De Meester J, Smits JM, Persijn GG, Haverrich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001;20:518–524.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296–302.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998;17:679–685.
    OpenUrlPubMedWeb of Science
  5. ↵
    Marcus JT, Vonk Noordegraaf A, De Vries PM, et al. MRI evaluation of right ventricular pressure overload in chronic obstructive pulmonary disease. J Magn Reson Imaging 1998;8:999–1005.
    OpenUrlPubMedWeb of Science
  6. ↵
    Sundaresan S. The impact of bronchiolitis obliterans on late morbidity and mortality after single and bilateral lung transplantation for pulmonary hypertension. Semin Thorac Cardiovasc Surg 1998;10:152–159.
    OpenUrlPubMed
  7. ↵
    Levine SM, Jenkinson SG, Bryan CL, et al. Ventilation-perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension. Chest 1992;101:401–405.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Pasque MK, Trulock EP, Cooper JD, et al. Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. Circulation 1995;92:2252–2258.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Starnes VA, Stinson EB, Oyer PE, et al. Single lung transplantation: a new therapeutic option for patients with pulmonary hypertension. Transplant Proc 1991;23:1209–1210.
    OpenUrlPubMedWeb of Science
  10. ↵
    Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111–117.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 21 Issue 1 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung
R.J. Roeleveld, A. Vonk Noordegraaf, W. van der Bij, P.E. Postmus, A. Boonstra
European Respiratory Journal Jan 2003, 21 (1) 192-194; DOI: 10.1183/09031936.03.00020902

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung
R.J. Roeleveld, A. Vonk Noordegraaf, W. van der Bij, P.E. Postmus, A. Boonstra
European Respiratory Journal Jan 2003, 21 (1) 192-194; DOI: 10.1183/09031936.03.00020902
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Case report
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endobronchial pseudo-tumour caused by herpes simplex
  • Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease
  • Metabisulphite-induced occupational asthma in a radiographer
Show more Case Studies

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society